EMERYVILLE, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today reported financial ...
Gritstone ground down by phase 2 cancer vaccine fail, sparking race against cash to gather more data
Gritstone bio’s gamble on a novel endpoint has backfired. The cancer vaccine failed to trigger hoped-for changes in circulating tumor DNA (ctDNA), causing the phase 2 trial to miss its primary ...
EMERYVILLE, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced ...
-- Newly developed EDGE-II model achieves superior predictive performance of HLA Class II presentation and CD4+ immunogenicity over publicly available models -- -- Combined with Gritstone's vaccine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results